Covaxin led to tolerable safety outcomes & enhanced immune responses, says Lancet

Even as a controversy rages over the safety of India’s first indigenous Covid-19 vaccine Covaxin after it was granted Emergency Use Authorisation (EUA) even as Phase III efficacy trials are underway, renowned medical journal Lancet said the vaccine, codenamed BBV152, led to tolerable safety outcomes and enhanced immune responses. “The overall incidence of solicited local and systemic adverse events in this study was 14-21% in all vaccine-treated groups, which is noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates.”